Endo reiterated at buy by Jefferies

Endo Pharmaceuticals Holdings Inc. was reiterated by Jefferies & Co., Inc. analyst David Windley at buy with a raised price target to $35. Jefferies believes Endo could beat consensus on better-than-expected sales of Lidoderm and its generic franchise; Lidoderm sales trend toward the high end of management's 2006 guidance of $530 million to $540 million. The analyst raised its 2006 earnings-per-share estimates to $1.75 from $1.72, with March quarterly expectations of $213 million in revenues and earnings per share of $0.44. Shares of the Chadds Ford, Pa., pharmaceutical company were up 66 cents, or 2.09%, at $32.20 on volume of 1,669,987 shares versus the three-month running average of 1,573,930 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.